Abbott Laboratories (ABT) Cash & Equivalents (2009 - 2026)

Abbott Laboratories has disclosed Cash & Equivalents across 18 years of filings, most recently posting $5.1 billion for Q2 2026.

• In Q2 2026, Cash & Equivalents fell 26.57% year-over-year to $5.1 billion; the TTM figure through Jun 2026 stood at $5.1 billion (down 26.57% YoY), while the FY2025 annual figure was $8.5 billion, up 11.9% from the prior year.
• Cash & Equivalents came in at $5.1 billion for Q2 2026 at Abbott Laboratories, down from $6.8 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $9.9 billion in Q4 2022 to a low of $5.1 billion in Q2 2026.
• Average Cash & Equivalents over 5 years is $7.6 billion, with a median of $7.5 billion recorded in 2024.
• Year-over-year, Cash & Equivalents gained 19.36% in 2023 and slumped 31.4% in 2024.
• Over 5 years, Cash & Equivalents stood at $9.9 billion in 2022, then sank by 30.22% to $6.9 billion in 2023, then climbed by 10.44% to $7.6 billion in 2024, then rose by 11.9% to $8.5 billion in 2025, then slumped by 40.11% to $5.1 billion in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $5.1 billion in Q2 2026, $6.8 billion in Q1 2026, and $8.5 billion in Q4 2025.